Introduction
Consequent to a review of the observations of an outpatient clinic's experience with Sudden Unexplained Death in Epilepsy (SUDEP), more than a decade ago, the hypothesis was proffered that there were no 'material risks', associated with SUDEP, to categorically mandate its discussion with every patient with epilepsy, irrespective of any other considerations [1] . A 'material risk' is a legal term, which forms part of the overarching duty of care that a clinician owes to his/her patient.
The definition of a 'material risk' was set out in the seminal Australian case of Rogers v Whittaker and stated that it was ''. . .material if it is a risk to which a reasonable person in the position of the patient would be likely to attach significance, or it is a risk to which the medical practitioner knows or ought reasonably to know the particular patient would be likely to attach significance in choosing whether or not to undergo a proposed treatment. . .'' [2] . It follows that a doctor, treating a patient with epilepsy, owes his/her patient a duty to advise or inform that patient of those facts which, it is expected, would directly impact on that patient's decision to accept, or reject, a proposed treatment. Rogers v Whittaker [2] departed considerably from the Bolam Principle, which was established in an English case and stated that ''. . .the test is the standard of the ordinary skilled man exercising or professing to have that special skill . . .in the case of a medical man, negligence means failure to act in accordance with the standards of reasonably competent medical men at the time. . .'' [3] .
The legal pendulum has swung to and fro, regarding the accepted legal expectations of that which the clinician must discuss with his/her patients but the need to explain 'material risks' has been widely accepted. It follows that if it can be established that there are 'material risks' associated with SUDEP then these need to be discussed with patients who have epilepsy.
The applicability of the Bolam test was reinforced in the Civil Liability Act, 2002 [4] , which incorporated a number of considerations including: -A professional does not incur liability re negligence if acting in a manner widely accepted by peer professionals; -Such reliance is negated if the Court considers that the opinion relied upon is irrational; -There may be more than a single professional opinion which does not preclude any or all being accepted; and -Peer professional opinion does not necessitate universal acceptance to constitute wide acceptance [4] .
What was set out in the clinic's experience of SUDEP [1] was that it could not establish any clear cut 'material risks', knowledge of which would directly influence a patient's willingness to accept, or reject, proposed treatment. This in no way negates the increased risk of premature mortality associated with a diagnosis of epilepsy [5] nor the fact that SUDEP represents the most common cause of death, as a direct consequence of having epilepsy [6] , but it negates an absolute requirement to discuss SUDEP unless information is sought.
It has now been a decade since that assessment was published [1] and the basic considerations, encapsulated in an understanding of both 'material risks' and the application of a consensus approach, as broadly outlined in both the Bolam Principle [3] and reinforced in the Civil Liability Act [4] , deserve to be revisited. What follows is an analysis of these two considerations, which underpin both the legal and ethical obligations that a clinician owes to his/her patients with epilepsy.
Material risks
Since the publication of the clinic's experience [1] there have been a number of attempts to further delineate the risks of SUDEP [6] [7] [8] [9] [10] [11] [12] and it is fundamental to the consideration of 'material risk' to review these findings. There is debate that SUDEP may be a periictal phenomenon [6] with a number of papers attesting to same [13] but only 2/3 of cases demonstrated evidence of preceding seizure [13] . Polytherapy, relying on more than a single antiepileptic medication, has been postulated as a risk factor for SUDEP [1, 12] but may not be an independent risk factor and may simply represent more refractory epilepsy [7] , which could suggest increased seizures as the pivotal factor. Untreated epilepsy, with associated seizures, is also a risk factor [7] . Both might suggest seizures themselves reflect causative factors, as polypharmacy is a direct consequence of failure to control with monotherapy and hence indicative of increased seizure frequency. As most SUDEP occurs in sleep, the use of monitoring devices or nocturnal supervision has been advocated to decrease risk [7] .
There has emerged growing evidence to support possible genetic predisposition to SUDEP [8, 9, 10, 11] . Hitiris et al. [14] identified respiratory arrest, cardiac dysrhythmia or asystole as the probable final common mechanism for SUDEP and these have been linked to genetic factors, particularly those associated with prolonged QT syndrome [8, 9] . People with prolonged QT may present with seizures as the initial presenting feature [14] and it is postulated that SCN1A, SCN1B and SCN5A (genes encoding for the sodium channels) and KCNQ1, KCNQ2, KCNQ3 and KCNH2 (genes encoding for the potassium channels) may be implicated both in SUDEP and long QT syndrome (LQTS) but it is far too early to be categorical about the association [9] . The SCNSA mutation has been found in SUDEP with idiopathic epilepsy [10] and the SCNIA mutation has been identified in patients with GEFS+ [8] and SUDEP with Dravet Syndrome [11] . Only time will tell if there is really a genetic predisposition to SUDEP but that would then need to be further explored to determine if this can translate into a form of intervention to prevent SUDEP occurring. The first step is to establish that the genetic predisposition exists and is not a coincidental finding.
Despite the attempts to identify unequivocal risk factors for SUDEP [1, 6, 7, 8, 9] , the findings have been conflicted, except for: young age; refractory epilepsy; early onset; convulsive seizures; male gender; and being in bed at the time of the SUDEP [12, 13, 14, 15, 16] . The ILAE Commission on Epidemiology; Subcommission on Mortality has added to this list to include use of lamotrigine as presenting higher risk, especially in those with idiopathic generalised epilepsy but retracted that assertion when reanalyzing the data [12] , indicating that no particular antiepileptic medication was associated with increased risk of SUDEP. The Subcommission concluded that it was the number of convulsive seizures rather than the type of medication which accounted for the increased risk of SUDEP [12] .
What these data indicate is that there remain no absolute 'material risks' attached to SUDEP which would unequivocally influence a patient's willingness or otherwise, to accept a treatment option. Poorly controlled epilepsy does carry with it an increased risk of SUDEP and fear of SUDEP, in such cases, may enhance patient compliance and an acceptance of the need to adhere to medical advice. It is axiomatic that patients attending a clinician, for the management of epilepsy, should be encouraged to follow the prescribed treatment and use of the discussion of SUDEP may offer an additional inducement. Having said same, there may be a cultural divide in which parents may bring their child for treatment yet still refuse anti-epileptic medications despite discussion of SUDEP [17, 18] . It follows that illness process and treatment must be addressed in a culturally competent manner, being aware of competing influences.
Application of Bolam Principle
Since the publication of the findings of the outpatient study of SUDEP [1] , there has been considerable debate regarding when and whom to tell about it [5, [19] [20] [21] [22] [23] [24] [25] [26] [27] . It remains controversial as to whether all patients should be told and when [19, 20, [24] [25] [26] [27] [28] [29] . The actual telling about SUDEP may have negative consequences [1, 28] causing psychological effects and even provoking non-epileptic seizures [28] .
The National Institute for Clinical Experience (NICE) [21] and the Scottish Intercollegiate Guidelines Network (SIGN) [22] both advocate provision of adequate SUDEP information to patients and their families. Some inconsistencies emerge from America where the taskforce of the Epilepsy Society and Foundation advocates disclosure re SUDEP [30] while the American Academy of Neurology [31] has avoided its inclusion within quality assurance for epilepsy [32] . In practice, only a minority of neurologists (5%) discuss SUDEP with all their patients [26] [27] [28] and most are selective with whom they discuss it. A third of US neurologists never discuss SUDEP with a similar proportion restricting discussion to those at increased risk [32] . Similar statistics applied to Italian neurologists, of whom almost 2/3 restricted discussion to selected more at risk patients [27] . When analysing patients records, 4.06% (14/345) had documented discussion of SUDEP [26] and the legal maxim is that if it is not documented, it did not happen.
On the basis of these data, it would appear that the majority of specialists who treat epilepsy do not routinely discuss SUDEP with their patients but do so if, and when, they perceive a need for providing additional information, especially for those patients at increased risk. This would appear at odds with some guidelines and with what some researches report to be patient expectation [21] [22] [23] [24] [25] 30] .
It follows that there is a majority of 'competent medical men' who do not routinely discuss SUDEP with all patients with epilepsy. These same clinicians are acting ''. . .in a manner widely accepted by peer professionals; the opinion relied upon is (not) irrational; and does not necessitate universal acceptance . . .'' as per the Civil Liability Act/s. Thus it seems established that selective discussion of SUDEP with those patients, considered at risk, complies with both the principles of the Bolam case and with subsequent legislated Australian standards to avoid liability in negligence.
The question arises whether neurologists, with a special interest in epilepsy, are more likely to discuss SUDEP when compared to general neurologists. This issue was specifically addressed by Xu et al. who surveyed more than 100 patients attending a tertiary referral hospital epilepsy clinic, over a period of one year, of whom only 14% were properly informed about the potential of SUDEP and of them the majority had obtained their information from either the Internet or popular press, rather than from their treating neurologist, despite it being a tertiary referral epilepsy service. The role of the epilepsy nurse specialist or advanced nurse practitioner, in possible discussion of SUDEP, has also attracted attention but this was not provided within the study by Xu et al. [33] . Involvement of such specialised nursing personnel would be predicated by (a) previous discussion of SUDEP by the attending physician, something that does not appear to be routinely practised in other than selected cases and (b) access to such specialised nursing staff who, more likely than not, would not be available to community-based clinicians where the majority of epilepsy is treated.
Access to SUDEP Action ( https://www.sudep.org/inquiriesindividualdeaths; accessed 06/02/2015) identified ''Inquiries into individual deaths'' -exploring Coroners' rulings on avoidable epilepsy-related deaths''. This identified 12 deaths of which one was thought to be SUDEP related, in a 35 year-old male in whom medical management was inadequate, in residential care, and was unrelated to discussion of SUDEP. It also identified the 2011 Inquiry into the deaths of Erin Casey and Christina Ilia and the earlier inquiry into Colette Findlay.
Erin Casey was 19 when she died, with sub-therapeutic blood levels of carbamazepine and poor adherence to her prescribed regimen. She failed to appreciate the seriousness of her epilepsy and lack of discussion of SUDEP resulted in complaint to the Scottish Public Service Ombudsman. Christina Ilia, with asthma and focal epilepsy, was 15 years at the time of her death. There was evidence of a seizure, with clenched fists, but SUDEP was noted on the death certificate.
In the analysis of risk factors for SUDEP, the coroner identified: ongoing convulsive seizures; young age; poor seizure control; learning disability; seizures during sleep; unwitnessed seizures; and non-adherence to medical regimen, all of which are relevant to poorly managed epilepsy. The coroner acknowledged that ''. . . The risk of SUDEP cannot be entirely eliminated. . .'', thereby raising questions of ''material risk''. It was accepted that triggers for seizures were also triggers for SUDEP and these existed irrespective of SUDEP, thereby justifying discussion, especially ''lifestyle'' issues. The coroner commented on nocturnal supervision of people with epilepsy and favoured use of nocturnal apnoea alarms, despite expert witnesses testifying that adherence with these devices was doubtful. As an accredited sleep physician, even with patients who have unequivocal sleep apnoea, it is often difficult to achieve compliance with continuous positive air pressure, which is a proven therapeutic intervention.
In both cases, the involved clinicians claimed failure to discuss SUDEP as a consequence of potential ''distress''. This is a clinical decision, based on the understanding of the prevailing doctorpatient relationship, which is directly influenced by the conditions at the time. In both cases, it is highly unlikely that these young people would have complied with nocturnal alarms, thereby making discussion thereof unlikely to change the risk factors. Especially in student accommodation, it is unlikely that the response to such alarm would have been adequate, thereby further suggesting that such discussion would have been 'immaterial'. The coroner stated, ''. . . Discretion must be left with the medical profession. . . There may well be families . . . where such a discussion would do more harm than good. . .''. The coroner was selective about what evidence to favour and ignored some literature [26] [27] [28] [29] which indicated that SUDEP was discussed on a case-by-case basis and far from universally by treating neurologists.
It is easy to be critical post hoc, once SUDEP, a truly tragic situation, has occurred, following which the blame game will emerge. In the decade, since the review of the ''legal obligations'' to discuss SUDEP [1] , both the application of material risks and Bolam has not changed greatly. It remains that, even in specialised epilepsy services, SUDEP is discussed with a minority of patients [33] . Where compliance is an issue, as was the case with Erin Casey, discussion of SUDEP may enhance adherence but equally the monitoring of blood levels of antiepileptic medications may be more effective and potentially more tangible to a teenager, with discussion of therapeutic windows and concrete evidence of noncompliance [34] .
Discussion
At the time of publishing the findings of a single outpatient epilepsy clinic's experience with SUDEP, and its deliberations concerning discussions with patients [1] , an ensuing debate emerged. This centred on the need to discuss SUDEP with all patients and was largely motivated by patient advocacy [23] [24] [25] . At the time of initial presentation, review of 'material risks', discussion of which would influence patient acceptance of treatment, was considered fundamental to the legal obligation to discuss SUDEP but there did not appear any such 'material risks' associated with SUDEP to mandate such discussion.
After a decade of endeavour, it would appear that the same fundamental risk factors have not changed greatly and the majority, with the exclusion of possible nocturnal monitoring [7] , cannot be modified other than to improve seizure management and compliance. There has emerged a suggestion of a genetic predisposition to SUDEP but this is far from confirmed [8, 9] and again, at least at this stage, cannot be modified and therefore does not constitute a 'material risk', which may result from treatment being offered. On this basis, the situation has not changed significantly in the last decade and there remains no 'material risk' that could be identified to demonstrate a failure of duty of care, if SUDEP is not discussed with all patients who have epilepsy.
Similarly, the application of the Bolam Principle, namely that few neurologists, irrespective of nationality, be it English, American or Italian, discuss SUDEP with all of their patients with epilepsy supports the approach of selective discussion. This does not preclude such discussion but rather leaves latitude to discuss it with those patients in whom such discussion may benefit the patient.
A patient has an indisputable right to receive honest and comprehensive answers to questions asked of their doctor. This includes questions related to SUDEP and where a patient seeks such information the doctor has a duty of care to openly discuss SUDEP to the best of that doctor's knowledge and unequivocally ''. . .in accordance with the standards of reasonably competent medical men at the time. . .'' [3] . It is unlikely that anyone, involved in this debate, would argue this point and thus further discussion concerning response to direct questioning is unwarranted. As the times have changed and there is greater exposure to information it is anticipated that more patients will ask, and be advised, about SUDEP.
Where the questions are not asked is where the difference of opinion arises. The data suggest that, in general, doctors do discuss SUDEP with patients who are at increased risk [19, 20, 24, 27, 28] . This is done as fear of SUDEP may provide a 'material risk' to encourage patients to be more compliant and adhere to medical advice. While fear of discussing SUDEP has been proffered as a reason for avoiding such discussion, to avert potential psychological consequences [1, 28] , where such discussion outweighs the risks to the patient, it appears clinicians are using SUDEP as a tool to improve patient protection. Culturally competent discussion of SUDEP, with patients who are non-adherent to prescribed treatment, may address the potential negative psychosocial impact of such discussion.
Just as no two patients are the same, no two patients present the identical management problems. It follows that there should not be a dogma which dictates that every patient should be treated identically. As set out in the discussion of 'material risk', discussion with a patient should comply with patient wishes and needs and these will vary between patients. What should not vary is the doctor's goal of being responsive to the patient's needs and to be prepared to discuss those issues, including SUDEP, which the patient needs to discuss, either to allay fears, to be simply better informed or to facilitate better adherence to treatment. Where such discussion has occurred this also should be documented within the patient's medical records to confirm that such discussion has occurred. Rather than being paternalistic, this is responsive medicine that is patient specific and will answer questions when raised or raise issues considered necessary to improve that patient's well being. This is the epitome of the 'art of medicine' that must always focus on the individual patient and that patient's needs, thereby acknowledging the established duty of care.
